These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7851876)

  • 1. The effect of chronic angiotensin converting enzyme inhibition on circulating prolactin in systemic hypertension.
    Haznedaroğlu IC; Tokgözoğlu L; Cağlar M; Kes S; Bekdik CF; Kabakçi G; Yörükan S; Uğurlu S
    Horm Metab Res; 1994 Oct; 26(10):491-3. PubMed ID: 7851876
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhanced response of plasma prolactin to metoclopramide during chronic converting enzyme inhibition.
    Dupont AG; Van der Nipen P; Van Steirteghem AC; Vanhaelst L
    Horm Metab Res; 1987 May; 19(5):212-5. PubMed ID: 3034757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enalapril decreases plasma prolactin levels in hypertensive patients.
    Lombardi C; Missale C; De Cotiis R; Spano PF
    J Biol Regul Homeost Agents; 1989; 3(3):128-30. PubMed ID: 2560316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Regulation mechanisms in prolactin secretion. Possible role of the hypophyseal renin-angiotensin system].
    Lombardi C; Missale C; Poli M; De Cotiis R; Memo M; Spedini C; Spano PF
    Minerva Med; 1990 Sep; 81(9):587-90. PubMed ID: 2234477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans.
    Petrov VV; Fagard RH; Lijnen PJ
    J Cardiovasc Pharmacol; 2001 Oct; 38(4):578-83. PubMed ID: 11588528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of angiotensin-converting enzyme inhibition on leptin and adiponectin levels in essential hypertension.
    Fontana V; de Faria AP; Oliveira-Paula GH; Silva PS; Biagi C; Tanus-Santos JE; Moreno H
    Basic Clin Pharmacol Toxicol; 2014 Jun; 114(6):472-5. PubMed ID: 24428812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of enalapril maleate on the lipid peroxidation processes and on the body's antioxidant system in patients with hypertension].
    Shapovalova SA
    Lik Sprava; 1999; (1):41-4. PubMed ID: 10423994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arterial responses in vitro and plasma digoxin immunoreactivity after losartan and enalapril treatments in experimental hypertension.
    Kalliovalkama J; Kähönen M; Tolvanen JP; Wu X; Voipio J; Pekki A; Doris PA; Ylitalo P; Pörsti I
    Pharmacol Toxicol; 2000 Jan; 86(1):36-43. PubMed ID: 10720105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Enalapril--an oral angiotensin-converting enzyme inhibitor: its pharmacological properties and clinical use].
    Wiecek A; Grzeszczak W
    Pol Tyg Lek; 1988 Feb; 43(9):279-83. PubMed ID: 2841654
    [No Abstract]   [Full Text] [Related]  

  • 10. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension.
    Napoli C; Sica V; de Nigris F; Pignalosa O; Condorelli M; Ignarro LJ; Liguori A
    Am Heart J; 2004 Jul; 148(1):e5. PubMed ID: 15215814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chronic inhibition of angiotensin converting enzyme on baroreceptor reflex in essential hypertension.
    Muratani H; Kimura Y; Matsumura K; Noda Y; Eto T; Fukiyama K
    Clin Exp Hypertens A; 1988; 10 Suppl 1():391-8. PubMed ID: 2854015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.
    van den Meiracker AH; Admiraal PJ; Derkx FH; Kleinbloesem C; Man in 't Veld AJ; van Brummelen P; Mulder P; Schalekamp MA
    J Hypertens; 1993 Aug; 11(8):831-8. PubMed ID: 8228207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin system phenotyping as a guidance toward personalized medicine for ACE inhibitors: can the response to ACE inhibition be predicted on the basis of plasma renin or ACE?
    Schilders JE; Wu H; Boomsma F; van den Meiracker AH; Danser AH
    Cardiovasc Drugs Ther; 2014 Aug; 28(4):335-45. PubMed ID: 24958603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated responses of brachial artery hemodynamics and renin-angiotensin system to acute converting enzyme inhibition by enalaprilat in essential hypertension.
    Levenson J; Chau NP; Billaud E; Simon A
    Am J Cardiol; 1988 May; 61(13):1056-60. PubMed ID: 2834938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of acetylsalicylic acid on hypotensive action of enalapril in hypertensive patients].
    Przewłocka-Kosmala M
    Przegl Lek; 2002; 59(2):76-8. PubMed ID: 12152253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of losartan and enalapril on erythropoiesis and renal function in hypertensive patients with renal parenchymal disease.
    Shand BI; Lynn KL
    Clin Nephrol; 2000 Nov; 54(5):427-8. PubMed ID: 11105808
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalapril.
    Ciulla MM; Paliotti R; Esposito A; Cuspidi C; Muiesan ML; Rosei EA; Magrini F; Zanchetti A
    J Hypertens; 2009 Mar; 27(3):626-32. PubMed ID: 19262230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients.
    Tezcan H; Yavuz D; Toprak A; Akpinar I; Koç M; Deyneli O; Akalin S
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):119-23. PubMed ID: 12806595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of angiotensin converting enzyme inhibitors on 1.25-(OH)2 D levels of hypertensive patients. Relationship with ACE polymorphisms.
    Pérez-Castrillón JL; Justo I; Sanz A; De Luis D; Dueñas A
    Horm Metab Res; 2006 Dec; 38(12):812-6. PubMed ID: 17163356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension.
    Oksa A; Gajdos M; Fedelesová V; Spustová V; Dzúrik R
    J Cardiovasc Pharmacol; 1994 Jan; 23(1):79-86. PubMed ID: 7511740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.